| Presentation |
Speaker |
| Introduction to CMHC Women's Health Summit |
Pamela B. Morris, MD |
| Cardio-oncology: Overview and the Intersection Between Breast Cancer and Cardiovascular Disease |
Ana Barac, MD |
| Cardiometabolic Risk in PCOS and Implications for Management |
Andrea Dunaif, MD |
| Impact of Pregnancy on CV Risk Factors and ASCVD Risk |
Pam R. Taub, MD |
| Choosing Wisely: Contraception in Women with Cardiometabolic Risk |
Nieca Goldberg, MD |
| Updates on the Role of Postmenopausal Hormone Replacement Therapy |
JoAnn E. Manson, MD |
| Women's Health Summit Expert Panel Discussion and Q&A |
Pamela B. Morris, MD; Ana Barac, MD; Andrea Dunaif, MD; Nieca Goldberg, MD; Pam R. Taub, MD; JoAnn E. Manson, MD |
| FDA Update and Late Breaking Trials |
Christie M. Ballantyne, MD; Deepak L. Bhatt, MD, MPH; Robert H. Eckel, MD; Keith C. Ferdinand, MD; Jay S. Skyler, MD |
| Keynote |
C. Ronald Kahn, MD |
| CME Lunch Symposium A - Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression |
Matthew R. Weir, MD; Robert D. Toto, MD; Lance Sloan, MD |
| CME Lunch Symposium B - Advances in HFpEF: Addressing Diagnostic and Treatment Challenges |
JoAnn Lindenfeld, MD' Keith C. Ferdinand, MD; Alanna A. Morris, MD |
| Where Are We With Devices for Diabetes Management? |
Anne L. Peters, MD |
| How Many GLP-1 RAs Do We Need and Why? |
John B. Buse, MD |
| CME Dinner Symposium - Mastering the Prior Authorization Process to Meet Patient Needs |
Pamela B. Morris, MD; Christie M. Ballantyne, MD; Kim K. Birtcher, PharmD; Matthew Stryker, PharmD, BCACP, CLS |
| CME Breakfast Symposium A - The ABC Access Program: Overcoming Barriers to Access of Newer Cardiovascular Agents for High-Risk and Minority Patients |
Keith C. Ferdinand, MD; Deirdre J. Mattina, MD; Catherine Davis Ahmed, MBA |
| CME Breakfast Symposium B - Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice |
Robert H. Eckel, MD; Harold E. Bays, MD; Deepak L. Bhatt, MD, MPH |
| Updates on Metabolic Surgery |
Mary-Elizabeth Patti, MD |
| Obesity and Environmental Influence: The Big Picture |
James O. Hill, PhD |
| Day to Day Management of Obesity in Clinical Practice |
Robert F. Kushner, MD |
| CME Lunch Symposium A� - Identifying, Diagnosing and Managing Iron Deficiency in Patients with Heart Failure to Improve Outcomes and Quality of Life |
Eldrin F. Lewis, MD, MPH; Akshay S. Desai, MD, MPH; Gurusher S. Panjrath, MD |
| CME Lunch Symposium B - New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia |
Robert E. Ratner, MD; Robert H. Eckel, MD; Davida Kruger, MSN, APN-BC, BCADM; Deborah J. Wexler, MD |
| How Aggressively Do We Lower LDL-C and For Which Patients? |
Vera A. Bittner, MD and Marc S. Sabatine, MD |
| Risk Assessment for Global Cardiovascular Disease: Imaging and Biomarkers |
Matthew J. Budoff, MD and James De Lemos, MD |
| Multidisciplinary Case Consults in Lipid Disorders |
Christie M. Ballantyne, MD; Vera A. Bittner, MD, MSPH; Robert H. Eckel, MD; Pamela B. Morris, MD; Margo B. Minissian, PhD, ACNP; Pam R. Taub, MD |
| CME Breakfast Symposium - Finding the Balance: Treatment and Management of Hyperkalemia in Patients with Heart Failure and Chronic Kidney Disease |
George L. Bakris, MD; Keith C. Ferdinand, MD |
| Overview of the New 2017 Hypertension Clinical Practice Guidelines |
George L. Bakris, MD |
| Comparing the Hypertension Guidelines - Where is the Equipoise? |
Michael A. Weber, MD |
| Patient Cases: How Would you Change the Management of Hypertension Based on the New Guidelines? |
Aldo Peixoto, MD; Michael A. Weber, MD; Keith C. Ferdinand, MD |
| Prevention of Heart Failure: The Next Frontier |
Peter A. McCollough, MD |
| Integration of Biomarkers and Prediction of AKI and Cardio-renal Outcomes in Clinical Practice |
Aldo Peixoto, MD |
| AKI and Heart Failure: How to Manage Compared to General Population? |
Peter A. McCollough, MD |
| Advanced CKD and Benefits from CVOTs |
Jorge Plutzky, MD |
